23 nov: USA: Ordreindgang på varige goder overrasker markant positivt
23 nov: Bavarian melder om fuldt hus i studie af koppevaccine
23-11-2016 15:23:05

Bavarian Nordic Completes Enrollment of Phase 3 Non-inferiority Study of IMVAMUNE® Smallpox Vaccine

Relateret indhold
22 maj - 
Bavarian vil opruste Danmarks bioberedskab med koppevac..
05 maj - 
Bavarian/Jyske: Sænker til "køb"
05 maj - 
Aktier/åbning: Vestas og TDC løfter C20 tættere på himl..
Relateret debat
25 maj - 
Tak igen Enkommentar for fine tanker og opsummering. I ..
25 maj - 
Lidt opdateringer på deltagelse i Prostvac pr den 1/6 2..
25 maj - 
Bamse godt skrevet og fanget - mon ikke der snart blive..

  • Second and final Phase 3 study to support a U.S. registration of liquid-frozen IMVAMUNE

COPENHAGEN, Denmark, November 23, 2016 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today announced the completion of enrollment of a Phase 3 clinical study designed to demonstrate non-inferiority between its investigational, non-replicating smallpox vaccine, IMVAMUNE and ACAM2000, the current U.S. licensed, and replicating smallpox vaccine. This is the second and final study agreed with the U.S. Food and Drug Administration (FDA) to support the registration of liquid-frozen IMVAMUNE. The first study, a lot consistency study in 4,000 healthy individuals, was successfully completed in 2015.

The Phase 3 non-inferiority study enrolled 440 subjects at a U.S. military garrison in South Korea led by the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) in collaboration with the U.S. Defense Health Agency. All subjects will have completed the study within second quarter of 2017, and top line data is anticipated in the second half of 2017.

Paul Chaplin, President & Chief Executive Officer of Bavarian Nordic, said: "Completion of enrolment of this study represents a significant milestone in the collaboration between Bavarian Nordic, and multiple federal agencies. IMVAMUNE has served as the cornerstone for our Company over the past decade and we will continue to work with the U.S. Government to meet their stated goal of protecting 66 million Americans who are in need of a safer smallpox vaccine. We look forward reporting these data and working with the authorities in the process towards U.S. licensure."

Bavarian Nordic has to-date delivered 28 million doses of liquid-frozen IMVAMUNE to the U.S. Strategic National Stockpile.

Federal funding acknowledgments

The Phase 3 study comparing the safety and immunogenicity of IMVAMUNE to ACAM2000 has been funded in whole or in part with Federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority, under Contract No. HHSO100200700034C

About Bavarian Nordic

Bavarian Nordic is a fully integrated biotechnology company focused on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases, based on the Company's live virus vaccine platform. Through long-standing collaborations, including a collaboration with the U.S. government, Bavarian Nordic has developed a portfolio of vaccines for infectious diseases, including the non-replicating smallpox vaccine, IMVAMUNE®, which is stockpiled for emergency use by the United States and other governments. The vaccine is approved in the European Union (under the trade name IMVANEX®) and in Canada. Bavarian Nordic and its partner Janssen are developing an Ebola vaccine regimen, which has been fast-tracked, with the backing of worldwide health authorities, and a vaccine for the prevention and treatment of HPV. Additionally, in collaboration with the National Cancer Institute, Bavarian Nordic has developed a portfolio of active cancer immunotherapies, including PROSTVAC®, which is currently in Phase 3 clinical development for the treatment of advanced prostate cancer. The company has partnered with Bristol-Myers Squibb for the potential commercialization of PROSTVAC. For more information visit www.bavarian-nordic.com or follow us on Twitter @bavariannordic.

Forward-looking statements

This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

Contacts

Rolf Sass Sørensen

Vice President Investor Relations (EU)

Tel: +45 61 77 47 43

Seth Lewis

Vice President Investor Relations (US)

Tel: +1 978 341 5271

Company Announcement no. 30 / 2016

2016-30-en


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Bavarian Nordic A/S via Globenewswire

Vedhæftet fil: 771658.pdf

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
19 maj
BAVA
tak til Kranen og andre, for at smide lidt guld ud i form af info.   Men guldet kom først her:   htt..
20
19 maj
BAVA
Slap dog af bamse. 1.000 i 2017 er et temmelig vildt gæt. Og det er vel at mærke et gæt, du giver jo..
15
25 maj
BAVA
Millenium har fundet ud af at det man at shorte bavarian er en rimeligt dårlig ide. De reducerer end..
9
21 maj
BAVA
Kik lige på vedlagte:   18/5 2017: https://clinicaltrials.gov/ct2/show/NCT00450463?term=prostvac&ran..
6
25 maj
BAVA
Lidt opdateringer på deltagelse i Prostvac pr den 1/6 2017 som vi jo snart når til.. For hver mdr de..
5
19 maj
BAVA
Nordea ser ud til at være enig i den betragtning. Nedenstående er morgenens flash news på nordea inv..
5
25 maj
BAVA
Ja det ser godt ud, en lille god nyhed og vi skal videre op. Jeg ved ikke med jer andre, men min for..
4
19 maj
BAVA
Det er bare fedt at Bava kom så stærkt tilbage. Dette sammen med tidligere nævnt insider tegn, gør a..
4
21 maj
BAVA
Du er da så snæversynet, som det kan lade sig gøre at være. I et tidligere indlæg i denne tråd skrev..
3
19 maj
BAVA
50 mia ville da være en fin pris. det halve er nok mere realistisk.   Men skulle det blive 50 mia, s..
3

Dong-topchef om salg af oliedivision: Den samlede pris er rigtig fin

24-05-2017 16:33:25
Flere iagttagere har kaldt salgsprisen for Dongs olie- og gasforretning lav, men hos energiselskabet selv mener man, at prisen er rigtig god, når man ser på det samlede regnestykke.Sådan lyder det fra Dongs administrerende direktør, Henrik Poulsen, efter at selskabet onsdag har gjort klar til et salg til den britiske kemikoncern Ineos.- Vi har fået en rigtig fin pris for forretningen. Vi har fået ..

Nordex-Acciona/dir: Har rigtig godt momentum i USA

24-05-2017 12:06:06
Den tyske vindmølleproducent Nordex, der for nylig overtog Acciona Windpower, har USA som et af nøglemarkederne, hvor selskabet venter at kunne fortsætte væksten fra et travlt 2017.- Vi har et rigtigt godt momentum i markedet, og i år kommer vil til at installere tæt ved 800 megawatt i USA siger Thomas Donoghue, som er salgschef for Nordex-Acciona på det nordamerikanske marked, til Ritzau Finans p..

Aktier/åbning: Salg af oliebiks sender Dong op i lyserødt marked

24-05-2017 09:07:05
Lige da alt så ud til at være ganske fredeligt før åbningen af det danske aktiemarked onsdag før den lange weekend, strøg Dong i fokus med nyheden om, at olie- og gasforretningen bliver solgt til kemivirksomheden Ineos.Dong satte forretningsdelen til salg i efteråret, og Dong har selv flere gange sagt, at et frasalg var ventet i løbet af 2017. Prisen kan løbe op i 8,7 mia. kr. og ændrer ikke ved 2..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge

Relaterede aktiekurser

Bavarian Nordic A/S 358,00 0,0% Aktiekurs uændret
Bavarian Nordic DKK10 53,40 0,0% Aktiekurs uændret

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2017  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
26. maj 2017 13:02:15
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20170517.1 - EUROWEB2 - 2017-05-26 13:02:15 - 2017-05-26 13:02:15 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x